← Back to Home

Selective T-cell activation: early invika trial shows signs of efficacy in refractory solid tumors

Among 27 patients in the appropriate dose groups, 4 had tumor shrinkage that met objective response criteria. This first-in-human trial offers new clues about resistance to immunotherapy, but how long the effects last and which patients are most likely to benefit remain to be confirmed.

By SURL BioNews

When cancer repeatedly evades treatment and even immunotherapy stops working, researchers face the challenge of how to remobilize the body's T cells. A first-in-human trial offers preliminary clues: after the experimental drug invikafusp alfa (invika for short) selectively activated specific T-cell populations, some patients with advanced solid tumors experienced tumor shrinkage. However, this remains an early study to identify doses and explore efficacy, and it does not yet provide sufficient evidence of improved survival.

The phase 1/2 monotherapy trial, called START-001, was published in *Nature Medicine* on October 23, 2026. According to Canada's University Health Network (UHN), the study treated 58 people at 10 cancer centers across four countries. The main analysis reported here covered 52 people with 21 types of advanced solid tumors; more than half had received at least four lines of treatment. With a data cutoff of March 12, 2025, the paper included 34 patients from the dose-escalation phase and the first 18 phase 2 patients. Most tumors had developed resistance to immune checkpoint inhibitor therapy.

Invika is a bispecific antibody that selectively activates T-cell populations bearing Vβ6 or Vβ10. UHN noted that these two populations together account for approximately one-tenth of all T cells and are also commonly found within tumors. The research team hopes this approach will focus the mobilization of immune activity involved in fighting cancer. The trial did observe increases in the targeted T cells in blood and tumors, providing evidence that the drug acts through its intended mechanism, but this alone does not mean patients experience lasting efficacy.

Among 27 patients who received the optimal biologically active doses of 0.08 or 0.12 milligrams per kilogram of body weight, 4 achieved an objective response, for a response rate of 14.8%. These included confirmed partial responses in patients with microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer. UHN also noted that 44.4% of patients in the same group experienced some degree of tumor shrinkage. This higher figure includes shrinkage that did not meet formal response criteria and cannot be used interchangeably with the objective response rate.

Another signal came from 18 patients who had developed resistance to immunotherapy: 66.7% achieved disease control. This means that tumors shrank or remained stable; it does not mean that everyone's tumors regressed substantially, nor can this percentage alone establish how long control lasts. Because patients differed in cancer type and treatment history, these findings are more useful for planning further research and do not yet support an inference that different cancer types will show similar effects.

Regarding safety, the most common treatment-related adverse event was cytokine release syndrome, predominantly grade 1 or 2. Two patients experienced reversible dose-limiting toxicities, and no treatment-related deaths were reported. After considering safety, pharmacokinetic and biological activity data together, the team selected 0.08 milligrams per kilogram as the recommended phase 2 dose. Whether the selective activation design can provide better safety still requires further data and comparative studies.

The study was sponsored and funded by the drug's developer, Marengo Therapeutics, with additional partial support from the US National Cancer Institute's Intramural Research Program. Co-senior author Lillian Siu disclosed that she serves as a scientific adviser to the company and holds equity in it. The phase 2 study is ongoing. Larger studies, more clearly defined patient subgroups and longer follow-up are needed to determine whether this T-cell activation strategy can translate short-term tumor changes into durable clinical benefits superior to those of existing treatments.

References

  1. Medical Xpress on MSN
  2. Nature Medicine via PubMed
  3. University Health Network